* Idera Pharmaceuticals Inc IDRA.OQ IDRA.O is expected
to show a no change in quarterly revenue when it reports
results on October 27 (estimated).
* Refinitiv's mean analyst estimate for Idera Pharmaceuticals
Inc is for a loss of 12 cents per share. For the same quarter
last year, the company reported a loss of 59 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.12 -0.18 -0.13 Beat 27.8
Mar. 31 2021 -0.22 -0.21 -0.14 Beat 34.9
Dec. 31 2020 -0.21 -0.23 -2.11 Missed -830.9
Sep. 30 2020 -0.22 -0.22 -0.59 Missed -168.2
Jun. -0.39 -0.39 -0.72 Missed -82.3
30 2020
Mar. 31 2020 -0.40 -0.41 -0.43 Missed -5.4
Dec. 31 2019 -0.39 -0.35 -1.76 Missed -400.5
Sep. 30 2019 -0.46 -0.46 -0.39 Beat 16.1
This summary was machine generated October 25 at 11:39 GMT. All
figures in US dollars unless otherwise stated